The Effect of Gonadotropin-releasing Hormone Agonist Pretreatment Therapy in Women with Ovarian Endometriosis Undergoing Frozen Embryo Transfer
Nguyen-Tuong Ho, Thi-My-Trang Luong,Yu-Ming Hu, Yen-Ping Ho, Shyr-Yeu Lin, Ruey-Sheng Wang, Yi-Xuan Lee, Shun-Jen Tan, Shu-Huei Kao, Chii-Ruey Tzeng
Abstract: We aimed to assess the impact of GnRH agonist (GnRHa) pretreatment on frozen embryo transfer (FET) cycles in women with ovarian endometriosis, utilizing a retrospective analysis of autologous FET cycles from ovulatory women diagnosed through ultrasound in combination with surgery, cyst aspiration, or elevated serum cancer antigen 125 (CA-125). Comparing two groups—one receiving depot leuprorelin 3.75 mg 4 weeks before FET and a control group—across 168 FET cycles revealed that GnRHa-pretreated women had notably higher implantation and clinical pregnancy rates (39.9% vs 24.0% and 60.9% vs 40.8%, respectively) despite similar blastocyst, euploidy status, and embryo quality metrics. Though not statistically significant, the pretreatment group also showed trends toward lower miscarriage and higher live birth rates. The outcomes such as gestational age at delivery, birth weight, and twin birth rate were comparable between groups. Multivariate regression analysis underscored GnRHa pretreatment as an independent enhancer of clinical pregnancy rate, suggesting that pituitary suppression before FET could significantly ameliorate pregnancy outcomes without adversely affecting neonatal outcomes in this patient population.
Keywords: Gonadotropin-releasing hormone agonist; frozen embryo transfer; ovarian endometriosis.
Biomedicines. 2024 Apr.16
The Effect of Gonadotropin-releasing Hormone Agonist Pretreatment Therapy in Women with Ovarian Endometriosis Undergoing Frozen Embryo Transfer
